Provided are therapeutic compositions, comprising: a polymeric nanoparticle; a ligand selected to activate an EGFR receptor; and a linker, the linker associating the nanoparticle and the ligand. Also provided are therapeutic compositions, comprising: a nanoparticle; a ligand, the ligand being any one of EGF, transforming growth factor-alpha (TGFα), heparin-binding EGF-like growth factor (HBEGF), betacellulin (BTC), amphiregulin (AREG), epiregulin (EREG), or epigen; and a linker associating the nanoparticle and the ligand, the therapeutic composition having a surface charge in the range of from about −5 to about 30 mV. Related methods of treatment are also provided.

The present disclosure relates to nanoparticle compositions for delivery of nucleic acid agents. The nanoparticle composition disclosed includes a carrier containing a dendritic polymer skeleton, a PEG moiety, an amine, and a hydrophobic unit. The size of the PEG moiety may be limited, potentially reducing or avoiding anti-PEG antibody induction.

The present technology is directed to composition that may be formulated for parenteral administration, where the composition includes a plurality of nanoparticles and optionally a pharmaceutically acceptable carrier. Each nanoparticle of the plurality includes a glatiramoid and one or more of a polyinosine-polycytidylic acid (Poly(I:C)), a plasmid DNA (pDNA), a CpG oligodeoxynucleotide (CpG ODN), or a combination of any two or more thereof.

Polymer-cargo-complexes including cross-linked copolymers and cargo molecules bound to the copolymers by electrostatic interactions. The non-medical use thereof for transfection and to a kit including such polymer-cargo-complexes. The polymer-cargo-complexes for use in therapy, in particular for use in gene therapy or peptide/protein drug delivery. A method of preparing the polymer-cargo-complexes. A kit for preparing a polymer-cargo-complex of the invention.

The present disclosure provides a method of delivery, treatment, and prevention of neuropathy and/or pain associated with NGF treatment for an underline disease or condition with a NGF mutant, such as NGF.sup.R100W, that does not elicit pain. The present disclosure further provides a composition of micro- and/or nano-rods attached with the NGF mutant, such as NGF.sup.R100W, which are injectable or administered to a target for desired therapies.

The present invention relates to three-dimensional self-assembled nucleic acid nanoparticles, a drug delivery system comprising the same, and a pharmaceutical composition for the prevention or treatment of acute kidney injury, which comprises the same. The three-dimensional self-assembled nucleic acid nanoparticles of the present invention, which have a tetrahedral structure, exhibit an excellent renal-targeting ability, and thus the nanoparticles conjugated with the pharmaceutically active ingredient for p53 exhibit excellent p53 and caspase 3 expression reductions in vitro and in vivo, and can thereby be applied to the prevention or treatment of acute kidney injury.

A multifunctional dendrimer nanoparticle and method of treating diseases of the posterior segment of the eye is presented. The functionalized polyamidoamine (PAMAM) dendrimer effectively delivers drugs and/or genes to the posterior eye, thereby providing for the effective, non-invasive, and topical treatment of diseased in the posterior eye. The multifunctional dendrimer nanoparticle has shRNA-encoding DNA and small molecule drug encapsulated cyclodextrin complexed to the outer surface of the dendrimer for delivery to the posterior segment of the eye.

The present disclosure provides lipid compositions comprising lipid particles (e.g., lipid nanodiscs), wherein the lipid particles (e.g., lipid nanodiscs) comprise a STING agonist amphiphile conjugate, a phospholipid and a PEG-lipid. The compositions are used in methods to induce or promote immune responses, such as immune responses useful for the treatment of cancer or infectious disease.

Disclosed, at least in part, are dosings of viral vectors concomitantly with synthetic nanocarriers attached to an immunosuppressant, in combination with dosings of the synthetic nanocarriers attached to an immunosuppressant without a viral vector or further dosings of the synthetic nanocarriers attached to an immunosuppressant concomitantly with doses of the viral vector, and related compositions that provide reduced humoral immune responses and/or increased or durable transgene or nucleic acid material expression.

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.